Indeed, the rapamycin delivered in this study to suppress mammary mTOR activity is an FDA-approved immunosuppressive drug, used to treat several types of cancer [25, 26] and recognized for its longevity-inducing effect [27]. The gene discussed is MTOR; the disease is cancer.